Trevi CFO granted 375,000 stock options

Trevi Therapeutics reported that its Chief Financial Officer, David C. Hastings, received a grant of stock options on January 8, 2026.

Rhea-AI Filing Summary

Trevi Therapeutics reported that its Chief Financial Officer, David C. Hastings, received a grant of stock options on January 8, 2026. The award covers 375,000 stock options to purchase common stock at an exercise price of $11.21 per share. According to the vesting schedule, 25% of the underlying 375,000 shares vest on January 8, 2027, with the remaining 75% vesting in equal monthly installments through January 8, 2030. After this grant, Hastings beneficially owns 375,000 derivative securities directly in the form of these options.

Insider Trade Summary

Grant/Award: 375,000 shares

Grant/Award 1 txn

Insider HASTINGS DAVID C

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	375,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 375,000 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Trevi Therapeutics (TRVI) report for its CFO?

The company reported that Chief Financial Officer David C. Hastings received a grant of 375,000 stock options to buy Trevi Therapeutics common stock.

What is the exercise price of the new stock options granted to the Trevi (TRVI) CFO?

The stock options granted to the CFO have an exercise price of $11.21 per share.

How do the 375,000 stock options for the Trevi (TRVI) CFO vest?

The 375,000 options vest as to 25% of the underlying shares on January 8, 2027, with the remaining 75% vesting in equal monthly installments through January 8, 2030.

How many derivative securities does the Trevi (TRVI) CFO hold after this Form 4 transaction?

Following the reported transaction, the CFO beneficially owns 375,000 derivative securities in the form of stock options, held directly.

Was the Trevi (TRVI) CFO stock option transaction a purchase or a grant?

It was a grant of stock options, reported with transaction code "A" and a price of $0 for the option itself, with an exercise price of $11.21 per share.

What is the expiration date of the Trevi (TRVI) CFO stock options?

The stock options granted to the CFO expire on January 7, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HASTINGS DAVID C

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.21	01/08/2026		A		375,000		(1)	01/07/2036	Common Stock	375,000	$0	375,000	D

Explanation of Responses:

1. This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.

	/s/ Christopher Galletta, attorney-in-fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.